#United States #Bethesda #Cancer Vaccine #Northwest Biotherapeutics #DCVax

Northwest Biotherapeutics Welcomes Dr. Annalisa Jenkins As Strategic Adviser

Northwest Biotherapeutics, Inc. (OTCQB:NWBO) is taking a significant step forward in the battle against glioblastoma and other solid tumors. The company has announced the appointment of Dr. Annalisa Jenkins, a highly respected leader in the biopharmaceutical field, as a strategic adviser. With over 25 years of experience in the industry, Dr. Jenkins has an impressive history of advancing innovative medical technologies. Her previous roles include leadership positions at significant pharmaceutical companies and FDA advisory committees, making her a valuable addition to the Northwest Biotherapeutics team.

Dr. Jenkins' Contributions to Biopharma

In her role, Dr. Jenkins will focus on further developing the company's dendritic cell-based cancer vaccine platform. This technology is central to NWBio's DCVax® therapeutics, which aim to provide personalized immune responses to treat solid tumors, including the challenging glioblastoma. This type of brain cancer has historically had poor survival rates, with little progress made over the past two decades. Dr. Jenkins believes that personalized, cell-based immunotherapies could significantly change treatment outcomes for not only glioblastoma but also other solid tumors that are responsible for the majority of cancer-related deaths worldwide.

Dr. Jenkins' notable achievements in biotech make her an ideal candidate for this strategic position. She previously served as President and CEO of Dimension Therapeutics, where she led the company to a successful public listing on NASDAQ and negotiated its acquisition by Ultragenyx. Additionally, her background includes executive positions at Merck Serono and Bristol-Myers Squibb. Her commitment to advancing therapies for severe diseases is backed by her distinguished recognition from the Order of the British Empire for her contributions to life sciences.

The Urgency of Advancing Cancer Treatments

During a recent statement, Dr. Jenkins underscored the critical need to develop innovative treatments for glioblastoma patients, who have seen virtually no improvement in survival rates over the last 20 years. "DCVax® is precisely the kind of innovative platform that deserves accelerated development and broader patient access," she remarked. This sentiment reflects NWBio's determination to push boundaries in cancer treatment, particularly amidst the stark reality of glioblastoma's grim prognosis.

NWBio's lead program, the DCVax®-L treatment, has already made headway with a Marketing Authorization Application submitted to the UK's Medicines and Healthcare Products Regulatory Agency (MHRA). This is an exciting juncture for the company as it seeks official approval to begin offering its unique treatment to patients.

In the larger context, Northwest Biotherapeutics aims to establish a leading position within the dendritic cell cancer vaccine space. Their platform is anticipated to extend its application to various types of solid tumors, overcoming the challenges posed by their inherent heterogeneity. This diverse approach is particularly crucial, as solid tumors account for about 90% of cancer cases globally.

Looking Ahead

Northwest Biotherapeutics’ leadership expresses palpable excitement regarding Dr. Jenkins’ appointment. Linda Powers, the CEO of NWBio, shared her enthusiasm about Dr. Jenkins' experience and vision for enhancing dendritic cell vaccines across a spectrum of solid tumors, including those rare types that often lack treatment options. The collaboration aims to accelerate the process of bringing essential new treatments to patients.

As NWBio forges ahead with Dr. Jenkins' guidance, the potential for groundbreaking advancements in cancer therapy appears promising. The focus on dendritic cell-based immunotherapies represents not just a response to an urgent medical need, but also a commitment to revolutionizing how solid tumors are treated, fostering hope for improved outcomes in a field where progress has been stagnant for far too long.

In conclusion, the collaboration between Dr. Annalisa Jenkins and Northwest Biotherapeutics marks a pivotal moment in the realm of personalized cancer therapy, positioning the company to potentially transform the landscape of cancer treatment to benefit patients worldwide.